Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Quizartinib

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 950769-58-1, Ac220, Quizartinib (ac220), Ac-220, Ac 220, Quizartinib hcl
    Molecular Formula
    C29H32N6O4S
    Molecular Weight
    560.7  g/mol
    InChI Key
    CVWXJKQAOSCOAB-UHFFFAOYSA-N
    FDA UNII
    7LA4O6Q0D3
    Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
    2.1.2 InChI
    InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
    2.1.3 InChI Key
    CVWXJKQAOSCOAB-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
    2.2 Other Identifiers
    2.2.1 UNII
    7LA4O6Q0D3
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ac220 Compound

    2.3.2 Depositor-Supplied Synonyms

    1. 950769-58-1

    2. Ac220

    3. Quizartinib (ac220)

    4. Ac-220

    5. Ac 220

    6. Quizartinib Hcl

    7. Ac010220

    8. Quizartinib Freebase

    9. Ac 010220

    10. Asp-2689

    11. 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea

    12. 7la4o6q0d3

    13. Chembl576982

    14. N-(5-tert-butylisoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

    15. Chebi:90217

    16. 950769-58-1 (free Base)

    17. Ac-010220

    18. 1132827-21-4 (hcl)

    19. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea

    20. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea

    21. N-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride

    22. Chembl2386811

    23. 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)-benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea

    24. N-(5-(1,1-dimethylethyl)isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1- B)benzothiazol-2-yl)phenyl)urea

    25. N-(5-(1,1-dimethylethyl)isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea

    26. Urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-n'-(4-(7-(2-(4-morpholinyl)ethoxy) Imidazo(2,1-b)benzothiazol-2-yl)phenyl)-

    27. Ac220 Compound

    28. Ac220,quizartinib

    29. Quizartinib [usan]

    30. Quizartinib [usan:inn]

    31. Quizartinibum

    32. Unii-7la4o6q0d3

    33. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea

    34. N-(5-tert-butylisoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea

    35. N-(5-tert-butylisoxazol-3-yl)-n'-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea

    36. Quizartinib, 95%

    37. Quizartinib, Ac220

    38. Quizartinib, Free Base

    39. Ac220 - Quizartinib

    40. Quizartinib [mi]

    41. Quizartinib; Plx3397

    42. Quizartinib [inn]

    43. Quizartinib (usan/inn)

    44. Quizartinib, Ac010220

    45. Schembl72923

    46. Quizartinib [who-dd]

    47. Mls006011240

    48. Gtpl5658

    49. Dtxsid70241746

    50. Bcpp000443

    51. Hms3244k09

    52. Hms3244k10

    53. Hms3244l09

    54. Hms3265g09

    55. Hms3265g10

    56. Hms3265h09

    57. Hms3265h10

    58. Hms3654j20

    59. Hms3743g21

    60. Bcp02224

    61. Bdbm50300690

    62. Mfcd18074524

    63. Nsc756647

    64. Nsc799659

    65. Nsc800857

    66. S1526

    67. Zinc43204002

    68. Akos015891557

    69. Bcp9000223

    70. Ccg-264906

    71. Cs-0211

    72. Db12874

    73. Nsc-756647

    74. Nsc-799659

    75. Nsc-800857

    76. Sb16610

    77. Ncgc00242493-01

    78. Ncgc00242493-02

    79. Ncgc00242493-07

    80. As-16178

    81. Hy-13001

    82. Smr004703000

    83. Ft-0687630

    84. Sw218131-2

    85. D09955

    86. J-524214

    87. Q7272714

    88. Brd-k93918653-001-01-4

    89. 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(12),3,5,8,10-pentaen-4-yl}phenyl)urea

    90. N-(5-tert-butyl-isoxazol-3-yl)-n''-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

    91. N-(5-tert-butyl-isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-ylethoxy)imidazo(2,1-b) (1,3)benzothiazol-2-yl)phenyl)urea

    92. N-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

    93. N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-n'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea

    2.4 Create Date
    2008-09-08
    3 Chemical and Physical Properties
    Molecular Weight 560.7 g/mol
    Molecular Formula C29H32N6O4S
    XLogP35.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count8
    Exact Mass560.22057470 g/mol
    Monoisotopic Mass560.22057470 g/mol
    Topological Polar Surface Area134 Ų
    Heavy Atom Count40
    Formal Charge0
    Complexity849
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of acute myeloid leukaemia.

    Treatment of acute myeloid leukaemia

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    In preclinical studies, Quizartinib demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).

    5.2 ATC Code

    L01XE

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01E - Protein kinase inhibitors

    L01EX - Other protein kinase inhibitors

    L01EX11 - Quizartinib

    5.3 Mechanism of Action

    Quizartinib potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.